Skip to main content

ORIGINAL RESEARCH article

Front. Oncol.
Sec. Surgical Oncology
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1533800
This article is part of the Research Topic Advancements in Robotic Surgery for Urologic Oncology: New Technologies, Innovations, and Surgical Techniques View all articles

The association between the interval from biopsy to radical prostatectomy and biochemical recurrence in patients with intermediate-and high-risk prostate cancer

Provisionally accepted
Carolin Siech Carolin Siech 1*Mike Wenzel Mike Wenzel 1Georgina Knoblich Georgina Knoblich 1Cristina Cano Garcia Cristina Cano Garcia 1Clara Humke Clara Humke 1Felix Preisser Felix Preisser 2Miriam Traumann Miriam Traumann 1Luis Alex Kluth Luis Alex Kluth 1Felix K. H. Chun Felix K. H. Chun 1Philipp Mandel Philipp Mandel 1
  • 1 Goethe University Frankfurt, Frankfurt, Hesse, Germany
  • 2 Martini Klinik Prostate Cancer Center, Hamburg, Hamburg, Germany

The final, formatted version of the article will be published soon.

    Objective: To investigate the association between the interval from biopsy to radical prostatectomy (RP) and biochemical recurrence (BCR) in prostate cancer patients. Methods: Within a tertiary-care database (01/2014 to 06/2023), D’Amico intermediate- and high-risk prostate cancer patients were stratified according to interval from biopsy to RP (≤3 vs. >3-≤6 months). Kaplan-Meier survival analyses and Cox regression models addressed BCR. Results: Of 680 patients, 328 vs. 153 exhibited intermediate-risk prostate cancer and had interval from biopsy to RP ≤3 vs. >3-≤6 months. Similarly, 158 vs. 41 exhibited high-risk prostate cancer and had interval from biopsy to RP ≤3 vs. >3-≤6 months. Median interval from biopsy to RP was 59 vs. 113 days in intermediate- and 55 vs. 117 days in high-risk patients, respectively. In both intermediate- and high-risk patients, rates of adverse histopathological outcomes, namely pT3/pT4, pN1, and R1 status, did not differ according to interval from biopsy to RP. In survival analyses, three-year BCR-free survival rates were 82 vs. 88% in intermediate-risk (p=0.5) and 76 vs. 75% in high-risk patients (p=1). In multivariable Cox regression models, BCR did not significantly differ according to interval from biopsy to RP in intermediate- (hazard ratio 0.85, 95% confidence interval 0.49-1.46; p=0.5) and high-risk patients (hazard ratio 1.05, 95% confidence interval 0.50-2.22; p=0.9). Conclusions: Both intermediate- and high-risk prostate cancer patients with an interval from biopsy to RP >3-≤6 months did not differ from those treated with RP ≤3 months after biopsy, regarding adverse histopathological outcomes and BCR rates. Therefore, it might be safe to postpone RP up to six months.  

    Keywords: BCR, prostate cancer, prostate biopsy, Radical Prostatectomy, Time to event

    Received: 24 Nov 2024; Accepted: 26 Dec 2024.

    Copyright: © 2024 Siech, Wenzel, Knoblich, Cano Garcia, Humke, Preisser, Traumann, Kluth, Chun and Mandel. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Carolin Siech, Goethe University Frankfurt, Frankfurt, 60325, Hesse, Germany

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.